MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Clinical trial NCT04769895 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04769895
Sponsor: MaaT Pharma
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Graft Versus Host Disease in Intestine Steroid Refractory GVHD

Start date: 2022-03-25
Primary completion: 2024-11-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.